Eli Lilly and Company (NYSE:LLY) Trading 1.9% Higher – Should You Buy?

Eli Lilly and Company (NYSE:LLY) was up 1.9% during mid-day trading on Thursday . The company traded as high as $1,189.59 and last traded at $1,185.31. 1,902,621 shares traded hands during mid-day trading, a decline of 40% from the average daily volume of 3,149,580 shares. The stock had previously closed at $1,163.01.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide delivered strong Phase 3 results in TRIUMPH-2 and TRIUMPH-3, supporting Lilly’s case for a future blockbuster obesity treatment and reinforcing its leadership in the GLP-1 market. Article Title
• Positive Sentiment: The company said it is preparing to file for FDA approval in Q1 2027, which keeps the long-term obesity pipeline on track even though the timeline slipped from an earlier target. Article Title
• Neutral Sentiment: Lilly is also moving ahead with a psychedelic medicine acquisition, signaling continued pipeline diversification beyond obesity and diabetes. Article Title
• Negative Sentiment: The FDA filing for retatrutide was pushed to early 2027 as Lilly gathers additional manufacturing and quality-control data, creating a modest timing setback for investors hoping for a faster launch. Article Title
• Negative Sentiment: Novo Nordisk has filed a lawsuit accusing Lilly of misleading advertising for Zepbound and Mounjaro, adding a legal overhang to the highly competitive obesity-drug market. Article Title

Wall Street Analysts Forecast Growth

Several research analysts have commented on LLY shares. The Goldman Sachs Group restated a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 22nd. Barclays increased their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Cantor Fitzgerald lifted their price objective on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a report on Monday, July 6th. Rothschild & Co Redburn upped their price objective on shares of Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Finally, Guggenheim upped their price objective on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,283.64.

Eli Lilly and Company Stock Performance

The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company has a market cap of $1.12 trillion, a PE ratio of 42.11, a price-to-earnings-growth ratio of 1.49 and a beta of 0.51. The business has a fifty day simple moving average of $1,129.17 and a two-hundred day simple moving average of $1,038.31.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s revenue was up 55.5% compared to the same quarter last year. During the same period last year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 34.21 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 24.58%.

Institutional Trading of Eli Lilly and Company

A number of institutional investors have recently modified their holdings of LLY. Vanguard Group Inc. raised its stake in shares of Eli Lilly and Company by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after acquiring an additional 1,006,885 shares in the last quarter. State Street Corp boosted its stake in Eli Lilly and Company by 1.8% in the fourth quarter. State Street Corp now owns 35,361,916 shares of the company’s stock valued at $38,002,744,000 after acquiring an additional 635,358 shares in the last quarter. Morgan Stanley grew its holdings in Eli Lilly and Company by 2.7% in the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock worth $16,757,510,000 after purchasing an additional 407,166 shares during the last quarter. Capital World Investors grew its holdings in Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after purchasing an additional 61,851 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Eli Lilly and Company by 10.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock worth $16,024,022,000 after purchasing an additional 1,432,069 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.